- $176.27m
- $204.73m
- $88.50m
Annual balance sheet for Biodesix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 32.7 | 43.1 | 26.3 | 26.2 | 19 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.66 | 5.07 | 7.68 | 8.6 | 9.04 |
| Total Other Current Assets | |||||
| Total Current Assets | 43.6 | 53.3 | 39.7 | 39.5 | 32.5 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.18 | 8.82 | 29.6 | 29.6 | 27.8 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 76.1 | 92.9 | 99.1 | 97.2 | 87.5 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 29 | 22.8 | 33.4 | 14.3 | 17.4 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 56.4 | 72.3 | 94.5 | 76.4 | 89.9 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 19.7 | 20.6 | 4.58 | 20.9 | -2.46 |
| Total Liabilities & Shareholders' Equity | 76.1 | 92.9 | 99.1 | 97.2 | 87.5 |
| Total Common Shares Outstanding |